← Back to Search

Gene Therapy

AdVEGFXC1 for Angina (EXACT Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by XyloCor Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of chronic angina due to obstructive coronary artery disease that is refractory to drug therapy and unsuitable for revascularization via coronary artery bypass graft or percutaneous coronary intervention
Angina class II-IV based on Canadian Cardiovascular Society Classification of Angina Pectoris
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

EXACT Trial Summary

This trial is testing a new treatment for angina caused by coronary artery disease. The treatment is a gene therapy that is delivered directly to the heart muscle. The goal is to see if the treatment is safe and if it can improve the patient's condition.

Eligible Conditions
  • Refractory Angina
  • Coronary Artery Disease
  • Cardiovascular Disease
  • Heart Disease
  • Ischemia

EXACT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have ongoing chest pain caused by blocked heart arteries that cannot be treated with medication or surgery.
Select...
You have moderate to severe chest pain, as defined by the Canadian Cardiovascular Society Classification of Angina Pectoris.

EXACT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Endpoint (adverse events)
Secondary outcome measures
Secondary Endpoint (Angina episodes)
Secondary Endpoint (Canadian Cardiovascular Society angina class)
Secondary Endpoint (Exercise tolerance test)
+1 more

EXACT Trial Design

4Treatment groups
Experimental Treatment
Group I: AdVEGFXC1 at 4x10^10 vpExperimental Treatment1 Intervention
Group II: AdVEGFXC1 at 1x10^9 vpExperimental Treatment1 Intervention
Group III: AdVEGFXC1 at 1x10^11 vpExperimental Treatment1 Intervention
Group IV: AdVEGFXC1 at 1x10^10 vpExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AdVEGFXC1
2020
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

XyloCor Therapeutics, Inc.Lead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research program accommodate individuals beyond the age of 35?

"This clinical study is seeking participants aged 18-80 inclusively."

Answered by AI

Who meets the criteria to be considered a participant in this trial?

"The study is looking for 41 coronary artery disease sufferers between the legal age of consent and 80 years old. Eligible applicants must also meet additional criteria, such as being a male or female with adequate contraception if they are capable of childbirth."

Answered by AI

Are there any active recruitment efforts for this investigation?

"This research trial is not presently accepting participants. As it was initially uploaded to clinicaltrials.gov on the 24th of January 2020, and most recently updated on July 7th 2022, this indicates that patient recruitment has concluded. However, there are still 1478 other medical studies actively seeking volunteers at present time."

Answered by AI

How many medical centers are currently hosting this research study?

"As of now, 17 medical facilities are hosting this trial. Locations include Allentown, Phoenix and Houston among others. It is imperative to choose the closest clinic in order to reduce travel-related strain should you decide to participate."

Answered by AI
Recent research and studies
~8 spots leftby Mar 2025